Benitec reports 100% response rate in BB-301 OPMD interim data
Benitec Biopharma has reported positive interim results from its ongoing Phase 1b/2a first-in-human study of BB-301, a gene therapy candidate for oculopharyngeal muscular dystrophy (OPMD)-related dysphagia. All nine patients treated across the trial's two dose cohorts met the statistical criteria for formal response, and no serious adverse events have been recorded in any participant to date.
The NASDAQ-listed company said the high-dose cohort (Cohort 2, three patients) showed greater relative improvements at the three-month post-treatment time-point compared with the low-dose cohort (Cohort 1, six patients). Specifically, 100% of high-dose patients met response criteria for improved throat emptying ability, versus 67% of low-dose patients. For functional swallowing capacity as assessed by the Cold-Water Timed Drinking Test, 67% of high-dose patients were classed as responders, compared with 17% at the lower dose. Both cohorts performed equivalently on total Sydney Swallow Questionnaire score (100% response in each) and throat closing ability (67% in each). Cohort 1 patients now have 12-month follow-up data available, supporting claims of durability.
The therapy and the indication
BB-301 uses Benitec's proprietary "Silence and Replace" DNA-directed RNA interference (ddRNAi) platform, delivered via a modified AAV9 capsid. The construct simultaneously silences the mutant PABPN1 gene responsible for OPMD and provides a codon-optimised functional replacement. Administration is local and one-time, directed to the pharyngeal muscles involved in swallowing, which the company says is designed to maximise benefit while limiting systemic exposure.
OPMD is a rare autosomal-dominant disorder affecting an estimated 15,000 patients across North America, Europe and Israel. Progressive dysphagia, which affects around 97% of patients, can lead to malnutrition, aspiration pneumonia and death. There are currently no approved disease-modifying therapies for the condition. BB-301 holds Orphan Drug and Fast Track designations from the FDA, as well as Orphan Drug Designation from the EMA.
Jerel A. Banks, executive chairman and chief executive, said the safety and efficacy profile seen so far "reinforces our conviction in the program and the potential to establish a new treatment paradigm for patients suffering from OPMD-related dysphagia." Benitec is targeting initiation of a pivotal study in mid-2027.
Market and competitive context
OPMD sits within the broader rare neuromuscular disease space, which has attracted sustained gene therapy investment on the back of regulatory frameworks that reward orphan programmes with expedited review pathways and, in the US, priority review vouchers. The field is competitive: AAV-based approaches have demonstrated durable expression in other muscle diseases, raising expectations that a single administration can sustain clinical benefit over years. Benitec's ddRNAi platform differentiates on the simultaneous silencing and replacement mechanism, which is arguably better suited to dominant-negative mutations like PABPN1 than straightforward gene addition strategies. The durability of Cohort 1 outcomes at 12 months will be closely watched as a signal of whether expression and effect are maintained. Full data were presented as a late-breaking abstract at the 2026 Annual Congress of the European Society of Gene and Cell Therapy, giving the results peer community visibility ahead of the pivotal programme.
With nine patients in a Phase 1b/2a study, the dataset remains small, and the open-label, uncontrolled design means confounding cannot be excluded. Investors and clinicians will look for a controlled pivotal readout and longer-term follow-up before drawing firm conclusions about BB-301's commercial prospects.